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This study evaluated the use of a chimpanzee-based adenovirus vaccine in mouse and Guinea pigs models of Zaire Ebola virus (ZEBOV)
infection. Vaccine vector expressing the envelope glycoprotein of ZEBOV was created from the molecular clone of chimpanzee adenovirus pan7
(AdC7). AdC7 vaccine stimulated robust T and B cell responses to ZEBOV in naı¨ve mice inducing complete protection to an otherwise lethal
challenge of ZEBOV. Complete protection to Zaire Ebola virus was also observed in Guinea pigs vaccinated with a relatively low dose of AdC7
(5  109/kg). Pre-existing immunity to AdHu5 was generated in mice following pre-exposure to AdHu5 or administration of pooled human
immune globulin. Pre-existing immunity to human adenoviruses severely compromised the efficacy of the human AdHu5 vaccine but not the
chimpanzee AdC7 vaccine. These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing
immunity to the vaccine carrier.
D 2005 Elsevier Inc. All rights reserved.Keywords: Adenovirus; Chimpanzee; Vaccine; Ebola; Mice; Guinea pig; Preexisting immunityIntroduction
Ebola virus is one of several pathogens that cause lethal
hemorrhagic fever (Sanchez, 2001). Most strains of Ebola have
a high fatality rate in humans. Outbreaks of Ebola infections
have occurred sporadically in Africa. While these outbreaks
have caused substantial fatalities, they remained well
contained. Identification of the natural reservoir for Ebola
viruses, which is believed to be wild animals, would help
understand and potentially prevent re-emergent infections. The
profile of Ebola virus infections that makes it such a dangerous
pathogen also contributes to its utility as a potential agent of
biological warfare. Development of an efficacious vaccine is
thus considered a high priority in spite of the limited impact of
Ebola virus on human morbidity and mortality world-wide.0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.10.042
* Corresponding author. Fax: +1 215 898 6588.
E-mail address: wilsonjm@mail.med.upenn.edu (J.M. Wilson).The Ebola envelope glycoprotein (GP) is the only viral
protein located on the envelope of the virus and presumably
directs its tropism (Feldmann et al., 1999; Ito et al., 2001). A
number of vaccine strategies including naked or lipid
encapsulated DNA, vaccinia, Venezuelan equine encephalitis
virus (VEE) and adenovirus have been evaluated for induction
of protection against challenge with Ebola virus (Geisbert and
Jahrling, 2003; Hart, 2003). All strategies have focused on a
subset of Ebola virus gene products as targets for eliciting
protective immune responses. Predominant work has utilized
the nucleoprotein (NP) as a target antigen for cellular immunity
and GP as a target antigen for both cellular and humoral
immunity (Hart, 2003; Wilson and Hart, 2001). Among those
strategies, an adenoviral vector was the only vaccine carrier
capable of protecting macaques against an otherwise lethal
dose of Zaire Ebola virus (Sullivan et al., 2000, 2003).
The use of replication-defective versions of adenoviruses in
gene therapy experiments illustrated the ability of these vectors
to generate vibrant T and B cell responses to both the capsid6) 394 – 401
www.e
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1996). Generating strong immunity to a transgene product such
as Ebola GP is desirable in the context of vaccine development.
However, immunity to adenoviral capsid proteins prevents
vector re-administration and thus limits application of this
vaccine carrier to a single dose per recipient (Kass-Eisler et al.,
1994, 1996). Therefore, vaccination necessitating prime/boost
strategy and/or protection against multiple pathogens may be
problematic. In addition, virtually all experiments performed to
date with adenoviral vectors utilized a construct based on
human serotype 5 (AdHu5). A significant proportion of the
North American population has evidence for pre-exposure to
AdHu5 (i.e., 30–50%) based on the presence of high levels of
neutralizing antibodies (NAB) in serum (Chirmule et al., 1999).
Recent isolation of several novel adenoviruses derived from
nonhuman primates raised the question whether they could be
used as vectors for vaccine application (Farina et al., 2001;
Fitzgerald et al., 2003; Roy et al., 2004a, 2004b). Indeed,
neutralization of chimpanzee-derived adenoviral vectors by
human serum was not significant suggesting that preexisting
immunity to human adenovirus could possibly be circum-
vented by chimpanzee adenovirus (Roy et al., 2004b). This
study evaluates specific T and B cell responses to Ebola GP
and their relative importance and response to lethal challenges
of ZEBOV following immunization in mice and Guinea pigs
with Chimpanzee AdC7 adenoviral vector expressing the Ebola
GP antigen. The immune response and protection mediated by
AdC7 vaccine vector is also evaluated in the presence of
preexisting immunity to human adenovirus.
Results
Vectors based on human adenovirus serotype 5 (AdHu5)
and the chimpanzee adenovirus pan7 (AdC7) were created to
express the full-length Zaire Ebola glycoprotein (ZGP) andFig. 1. B10.BR mice were vaccinated intramuscularly (I.M.) with 5  1010 particles
for frequency analysis. A specific or control non-specific peptide to ZEBOV/GP wa
the cells were subsequently analyzed by flow cytometry for expression of CD8 an
peptide: control non-specific to Ebola GP. Groups of 3–4 mice were analyzed
representative experiment.tested in mice for induction of T and B cell responses. Peptide
specific activation of CD8+ T cells, as measured by the
production of IFN-g, was detected in both AdHu5-ZGP and
AdC7-ZGP vaccinated animals at frequencies equal to 12 T 3
and 14 T 2%, respectively (Fig. 1). Mononuclear cells
stimulated with control unspecific peptide demonstrated
background levels with 0.4 to 0.5% of CD8+ T cells positive
for INF-g (Fig. 1). The B cell response to the Ebola envelope
was analyzed by measuring sera from immunized mice for
neutralization of a LacZ expressing HIV-based vector pseudo-
typed with the Zaire Ebola glycoprotein (ZGP). Neutralizing
antibody (NAB) to ZGP-pseudotyped HIV vector could be
detected in mice 30 days after vaccination with AdHu5-ZGP
and AdC7-ZGP at levels, in terms of reciprocal dilution, equal
to 90 T 10 and 100 T 16 (N = 5 per group, repeated 4 times),
respectively.
The most direct means of evaluating the efficacy of these
vaccines in mice is to assess protection against weight loss and
death following lethal challenge with mouse-adapted Zaire
Ebola virus (Bray et al., 1998). Mice were immunized with a
single dose of 5  1010 particles per animal as performed
previously and vaccinated animals were challenged with 200
LD50 of the mouse-adapted strain of ZEBOV 21 days later. All
control mice (vehicle and AdHu5-LacZ) died between days 5
and 9 post-challenge. In contrast, all mice vaccinated with
AdHu5-ZGP or AdC7-ZGP survived the challenge with
mouse-adapted ZEBOV (Fig. 2). Weight loss was observed
only from control groups (vehicle and AdHu5-LacZ, data not
shown). Complete protection following vaccination with 5 
1010 particles of AdC7-ZGP was demonstrated with challenge
doses of ZEBOV up to 200,000 LD50, which was the highest
dose tested (data not shown).
A number of additional parameters relevant to protection
following vaccination were studied. AdC7-ZGP vaccine was
administered at doses ranging from 106 to 1010 particles perper animal of the indicated vectors and splenocytes were harvested 10 days later
s (0.4 Ag/well) incubated with 106 splenocytes in the presence of Brefeldin and
d gamma interferon. ZEBOV/GP peptide: specific to Zaire Ebola GP, Control
per vector and the experiment was repeated 4 times. Data originate from a
Fig. 2. Protective efficacy of Adhu5 and AdC7 expressing the Zaire Ebola GP. Groups of 12 BALB/c mice were vaccinated I.M. with 5  1010 particles per animal.
Three weeks post-vaccination, all mice were challenged with 200 LD50 of mouse-adapted Zaire Ebola virus. Data represent percent survival.
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adapted Ebola Zaire virus was observed down to a dose equal
to 5  109 particles per mouse while partial protection (80%
survival) was obtained with 5  108 particles per mouse (Table
1). No protection was seen at doses equal or lower than 5  107
particles per mouse. Another important feature of the use of
adenovirus vectors in this setting is the time course by which
protection is achieved. In experiments summarized in Fig. 3,
animals were immunized with AdC7-ZGP vector and chal-
lenged 5, 10, and 15 days later. Partial protection was observed
as early as 5 days and total protection was achieved from day
10 on after vaccination.
A significant concern regarding the use of AdHu5 based
vaccines is the potential interference of preexisting immunity to
natural human adenovirus infections on vaccine efficacy.
Experiments were performed to evaluate this concern. To
mimic pre-existing immunity, mice were pre-exposed to
AdHu5 expressing a non-relevant antigen, h-galactosidase, or
administered with pooled human immune globulin. For pre-
exposure, mice were administered AdHu5-LacZ vectors
intramuscularly in order to activate T and B cells against the
adenovirus serotype capsid and elicit humoral immunity
slightly lower to what is observed in humans following
natural infections. Five groups were studied including no
preimmunization and no vaccine (group 1), vaccination with
AdHu5-ZGP without (group 2) and with (group 3) preimmu-
nization with AdHu5-LacZ, and vaccination with AdC7-ZGP
without (group 4) and with (group 5) preimmunization with
AdHu5-LacZ. Fig. 4 shows that preimmunization with
AdHu5-LacZ resulted in NAB titer against AdHu5 equal to
1:320 with no detectable NAB to AdC7. Without preimmu-
nization, the AdHu5 and AdC7 based vaccines generated
equivalent levels of ZGP-HIV-LacZ NAB and ZGP-specific
IFN-g expressing CD8 T cells (Figs. 4B and C). Preimmu-Table 1
Survival of vaccinated mice with different doses of AdC7-ZGP following
challenge with mouse-adapted Ebola virusa
Vector doseb 5  106 5  107 5  108 5  109 5  1010
AdC7-LacZ 0/10 0/10 0/10 0/10 0/10
AdC7-ZEBOVGP 0/10 0/10 8/10 10/10 10/10
a Group of 10 BALB/c mice were vaccinated intramuscular and challenged
with 200 LD50 of mouse-adapted ZEBOV 3 weeks later.
b Doses of AdC7 vector represent particles administered per mouse by
unique injection. Numerator represents the number of surviving mice out of 10.nization with AdHu5-LacZ completely interfered with the
ability of the AdHu5 vaccine to produce NAB and diminished
induction of antigen-specific T cells by 85%. In contrast, the
presence of preexisting immunity to AdHu5 did not severely
compromised the ability of the AdC7 vaccine to produce
NAB or antigen specific T cells although the average NAB
level was down by 29% (P = 0.1) and IFN-g positive T cells
level by 21% (P = 0.03).
These experiments were also performed in order to assess
the impact of preexisting immunity on survival following lethal
challenge with mouse-adapted ZEBOV. Preimmunization with
AdHu5-LacZ did elicit AdHu5 NAB at titers equal to 1:320
without detectable NAB to AdC7, however, antivector NABs
were not detected in mice prior to adenovirus exposure or in
naı¨ve animals (data not shown). In these experiments,
vaccination of naı¨ve mice with either AdHu5-ZGP or AdC7-
ZGP vectors afforded complete protection as observed previ-
ously. In contrast, preimmunization with AdHu5-LacZ signif-
icantly diminished efficacy of the AdHu5 vaccine as evidenced
by substantial weight loss (Fig. 5) and 70% mortality (Fig. 4A)
without any detectable impact on efficacy of the AdC7 vaccine
(Figs. 4A and 5).
In the presence of pre-existing immunity to AdHu5, T and B
cell responses to the Ebola antigen expressed by AdC7 vector
were slightly reduced, possibly reflecting antigenic similarity
between chimpanzee and human adenoviruses. This was
further addressed by passive transfer of pooled human immune
globulin, containing antibodies to common human serotypes of
adenovirus including AdHu5 (Casimiro et al.), into mice prior
to vaccination. Intravenous injection of pooled human Ig 24
and 2 h before vaccination resulted in anti-AdHu5 titer in the
blood of recipients equal to 1:1280. This approach essentially
reconstitutes the full spectrum of anti-Ad humoral immunity
found in humans in contrast to the experiment described above
with AdHu5-LacZ pre-immunization which generates cellular
and humoral immune responses against AdHu5 serotype only.
As shown in Fig. 6, passive transfer of pooled human Ig
seriously compromised the efficacy of the AdHu5-ZGP vaccine
with no survivors following challenge and a diminished T cell
response (84% down) with no detectable NAB. In contrast, the
same conditions did not have a detectable impact on the
protective efficacy of the AdC7-ZGP vaccine (i.e. 100%
survivors) although a statistically not significant diminution
in the average of T and B cell responses was observed (down
by 15%, P = 0.1 and 19%, P = 0.2, respectively).
Fig. 3. Survival of BALB/c mice vaccinated with AdC7-ZGP at different time points before challenge with mouse-adapted Zaire Ebola virus. Groups of 10 BALB/c
mice were vaccinated I.M. with 5  1010 particles per animal and challenged after 5, 10 or 15 days with 200 LD50 of mouse-adapted ZEBOV. Data represent percent
survival.
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mice but failed in animal models such as Guinea pigs or
nonhuman primates which are more representative of a
ZEBOV infection in humans. Therefore, additional studies
were performed in Guinea pigs to evaluate whether chimpan-
zee AdC7 could be protective in a more stringent model of
ZEBOV infection. Groups of 6 Guinea pigs were vaccinated
with AdC7-ZGP at 5  109, 5  1010 or 5  1011 particles per
kilogram and challenged I.P. 28 days later with 1000 plaque-
forming units of Guinea pigs-adapted ZEBOV. As shown in
Table 2, 100% of vaccinated Guinea pigs survived the
challenge with ZEBOV which otherwise killed all unvaccinat-
ed control animals. Protection correlated with the presence of
serum NAB which significantly increased with higher vacci-
nation doses. All vaccinated Guinea pigs demonstrated a steadyFig. 4. Impact of preexisting immunity to AdHu5 on vaccine efficacy. B10.BR (T
preimmunized with AdHu5-LacZ (5  1010 particles I.M.) and subjected to variou
without (group 2) and with (group 3) preimmunization and vaccination with 5
preimmunization and vaccination with 5  1010 particles of AdC7-ZGP. (A) Surviva
of IFN-g expressing CD8+ T cells to ZGP epitope at day 10 post-vaccination (N =
after vaccination (N = 10/group, repeated 2 times). Error bars represent the standarweight gain that was similar among all groups (data not
shown).
Discussion
The work of Nabel and colleagues clearly established the
potential of adenovirus vaccine platform in the development of
a vaccine against Ebola virus. They demonstrated protection in
cynomolgus macaques to lethal challenge with ZEBOV 28
days after a single intramuscular injection of 2  1012 particles
of a mixture of AdHu5 vectors expressing Ebola NP and GP.
While these studies are extremely encouraging, a number of
issues require further evaluation in the context of the further
development of this approach. This study addresses efficacy of
chimpanzee adenovirus-based vaccine vector against Zairecell assay) and BALB/c (B cell assay and challenge experiments) mice were
s vaccine strategies as follows: no preimmunization and no vaccine (group 1),
 1010 particles AdHu5-ZGP, and without (group 4) and with (group 5)
l following 200 LD50 of mouse-adapted ZEBOV (N = 10/group). (B) Frequency
4/group, repeated 3 times). (C) NAB to Ebo-pseudotyped HIV vector at day 30
d deviation of the data.
Fig. 5. Body weight of vaccinated BALB/c mice with preexisting immunity following challenge with mouse-adapted ZEBOV. Challenged mice were weighed
everyday from day 1 to day 11 post-infection. Weight is expressed as the average body weight from each mouse of a group of 10 mice.
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adenoviruses.
A number of groups have surveyed human populations for
NAB against AdHu5. Over 30% of subjects in Western
civilizations have substantial levels of AdHu5 NAB while
the frequency of AdHu5 NAB increases to over 90% of
subjects in some third world populations (Chirmule et al.,
1999; Mast, 2003). Several studies have shown that AdHu5
NAB do indeed compromise AdHu5 based vaccines, including
a murine model of rabies in which rabies NAB and protection
to lethal dose of rabies was measured as well as murine and
nonhuman primate models of HIV vaccines in which antigen
specific T cell frequencies were measured (Casimiro et al.,
2003; Fitzgerald et al., 2003; Xiang et al., 2002). Preliminary
results from the Merck HIV vaccine study are consistent with
this hypothesis in that the number of subjects responding to the
AdHu5 vaccine was diminished in those with preexistingFig. 6. Impact of pre-existing immunity to AdHu5 with pooled human Ig (h-Ig) on v
experiments) mice were injected intravenously with pooled h-Ig 24 and 2 h before v
with (group 3) h-Ig and vaccination with 5  1010 particles AdHu5-ZGP, and witho
AdC7-ZGP. (A) Survival following 200 LD50 of mouse-adapted ZEBOV (N = 10/gr
post-vaccination (N = 4/group, repeated 2 times). (C) NAB to Ebo-pseudotyped HIV
represent the standard deviation of the data.AdHu5 NAB (Emini, 2002). Some studies indicate that
preexisting immunity to human adenovirus can be bypassed
with high doses of AdHu5 or priming with DNA prior to
immunization with AdHu5 (Gao et al., 2003b; Wu et al., 2005;
Yang et al., 2003). However, the clinical relevance of these
strategies remains to be demonstrated as they involve quantities
of AdHu5 that are several orders of magnitude above the
highest dose evaluated in humans or necessitate multiple
injections which preclude rapid intervention.
To evaluate the issue of pre-existing immunity for Ad-based
vaccination against Ebola virus, we focused on the murine
model in which BALB/c mice were challenged with a mouse-
adapted strain of ZEBOV. This leads to 100% mortality with
dose of challenge as low as 1 pfu/animal (Bray et al., 1998).
The murine model has been criticized because it appears less
stringent a test of vaccine efficacy than the nonhuman primate
model. A number of vaccine strategies that succeeded in theaccine efficacy. B10.BR (T cell assay) and BALB/c (B cell assay and challenge
accination as follow: no h-Ig and no vaccine (group 1), without (group 2) and
ut (group 4) and with (group 5) h-Ig and vaccination with 5  1010 particles of
oup). (B) Frequency of IFN-g expressing CD8+ T cells to ZGP epitope at day 10
vector at day 30 after vaccination (N = 10/group, repeated 2 times). Error bars
Table 2
Survival of AdC7-EboZ vaccinated Guinea pigs following challenge with
Guinea pigs-adapted Zaire Ebola virus
Dose of AdC7-ZGP/kga Percentage survival (%) NABb
Vehicle 0 0
5  109 100 20 T 0
5  1010 100 53 T 23
5  1011 100 267 T 92
a Group of 6 Guinea pigs were vaccinated I.M. with the appropriated number
of AdC7-ZGP particles per kilogram and challenged I.P. with 1000 pfu of
Guinea pigs-adapted ZEBOV 4 weeks later. One control group of 3 Guinea pigs
was administered with saline (vehicle) and challenged as described above.
b Reciprocal dilution of NAB titers to Ebo-pseudotyped HIV vector at day
21 after vaccination (N = all animals/group, repeated two times).
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Jahrling, 2003; Hart, 2003). Our studies showed that AdHu5
NAB levels of 1:320 severely compromise the ability of the
AdHu5 vaccine to activate T and B cells to ZEBOV and to
protect against a lethal challenge of ZEBOV. Analysis of 52
normal human subjects for AdHu5 NAB revealed levels largely
in excess of 1:320 in 32% of these human samples. The
diminished efficacy of high dose AdHu5-ZGP in the setting of
clinically relevant AdHu5 NAB is particularly worrisome in
light of the previous concerns regarding low stringency of the
murine model. Indeed, loss of vaccine efficacy due to vector
directed NABs in a model that is reportedly easy to protect
does not bode well for the efficacy of this vaccine in a more
stringent model (i.e., nonhuman primates) with AdHu5 NABs.
The critical next step is to modify the adenovirus vaccine
strategy to overcome the problem of pre-existing immunity.
Yang et al. (2003) showed improved AdHu5 potency in the
setting of AdHu5 NAB following prime with naked DNA.
While this is clearly worth pursuing, it would preclude the use
of the adenovirus vaccine as a rapid single dose vaccine, which
we show is effective in the mouse model within 10 days, and
Nabel and colleagues showed it was effective in the nonhuman
primate within 28 days. We and others have pursued an
alternative approach using adenoviruses as vectors in which
neutralizing activity is relatively low in human populations. An
example of a human derived adenovirus with this property is
serotype 35 which together with serotype 11 have recently been
shown to partially bypass preexisting immunity to human
adenovirus 5 (Lemckert et al., 2005). Our strategy is to
characterize and develop as vectors adenoviruses from nonhu-
man primates with AdC7 as the prototype. Human sera have
very little neutralizing activity against AdC7 and the E1 deleted
virus, generated from a molecular clone, is grown to high levels
with no contamination with replication competent adeno-
viruses.
Lethal challenge of Guinea pigs with different doses of
AdC7-ZGP resulted in complete protection against Zaire Ebola
virus. Interestingly, the lower dose of AdC7-ZGP at 5  109
particles per kilogram was as protective (no weight loss or
clinical signs of sickness) as the higher doses although the
average NAB level was lower at 1/20 (compared to 1/53 and
1/267). This is surprising considering that per weight the
protective dose of AdC7-ZGP is lower in Guinea pigs than inmice (5  109 and 2.2  1011 particles/kg, respectively) despite
the fact that the Guinea pigs model is view by many as more
stringent than the mice model. At this point, we cannot rule out
that the chimpanzee AdC7 vaccine vector is sub-optimal in
mice and perform better in larger mammals. This observation
also suggests that AdC7-ZGP could potentially be scalable as a
single dose for application in humans since AdHu5-based
vaccine was administered to individuals at doses approximat-
ing 1.3  109 particles/kg (1  1011 particles/individual,
(Emini, 2002). However, formal assessment of the optimal
dose would be required as studies indicate that animals do not
accurately predict toxic or effective doses of adenovirus in
humans (Raper et al., 2002; Schnell et al., 2001).
In the current study, AdC7-ZGP vector was as potent as
AdHu5-ZGP vector in naı¨ve mice which developed a strong T
and B cell responses with both vector. In addition, 5  109
particles/kg of AdC7-ZGP was sufficient to fully protect
Guinea pigs from a lethal challenge with ZEBOV. Importantly,
pre-existing immunity to AdHu5 had only a slight impact on T
and B cell responses generated by AdC7-ZGP in mice and
none on survival following challenge with mouse-adapted
ZEBOV. The next step is formal evaluation of this approach in
nonhuman primates. Pilot studies of rhesus macaques vacci-
nated with AdC7-EboGP showed detectable antigen specific T
cell responses and levels of ZEBOV NAB comparable to that
seen in mice. This study was performed using mouse- or
Guinea pig-adapted strains which exhibit some mutations
leading to amino acid changes compared to human ZEBOV.
Stocks of chimpanzee adenovirus Ebola vaccine vector were
recently produced for evaluation in nonhuman primates against
human ZEBOV to assess efficacy in a more relevant model of
Ebola hemorrhagic fever.
Materials and methods
Construction and production of adenoviral vectors
Molecular clones of E1-deleted and/or E1/E3-deleted
human and chimpanzee adenovirus vectors expressing ZEBOV
glycoprotein were created using a green-white selection
method as described previously (Gao et al., 2003a). Correct
molecular clones were confirmed by sequencing. The viral
vectors were rescued by transfecting the linearized molecular
clones into 293 cells, propagated to large-scale infections (1 
109 cells) and purified by the standard CsCl gradient
sedimentation process. Genome structures of vectors were
analyzed by restriction digestions of viral DNA in comparison
with those of the molecular clones. Infectivity of vectors was
determined by the standard plaque assay on 293 cells.
Animal models
BALB/c mice were used to evaluate protection lethal doses
of mouse-adapted Zaire Ebola virus since it is the preferred
strain of mice for BSL-4 related experiments based on a
number of technical and safety issues. Antibody responses to
ZGP were measured in BALB/c and B10.BR as indicated. The
G.P. Kobinger et al. / Virology 346 (2006) 394–401400T cell response was analyzed by evaluating the frequency of
CD8+ T cells positive for INF-g production upon peptide
stimulation by flow cytometry (FACS) in B10.BR (MHC H-
2K) where a dominant CD8 epitope has been mapped. Analysis
for CD8+ T cell activation in response to vaccination in BALB/
c was not possible because screening of a peptide library
encompassing the Ebola GP failed to identify a restricted
dominant epitope in this strain of mice (MHC H-2D). However,
experiments in C57BL/6 mice revealed that the amount of
specific cell lysis monitored by Cr51 release (CTL assays)
following incubation of target cells with activated cytotoxic
lymphocytes (effector cells) was comparable to data accumu-
lated in B10.BR and correlated with protection efficacy
observed in BALB/c mice (data not shown). Hartley guinea
pigs were between 300 and 400 g at the time of vaccination.
Immunization of guinea pigs and mice with adenoviral vectors
and challenge
Guinea pigs, BALB/c, and B10.BRmice were immunized by
intramuscular injection in the right limb with 100 Al of
recombinant adenoviral vector diluted in PBS. Guinea pigs
and BALB/c mice were challenged by intraperitoneal injection
with indicated doses of the Guinea pigs-adapted or mouse-
adapted Zaire Ebola virus strain Mayinga. The mouse-adapted
strain of ZEBOV was isolated following nine serial passages of
the human strain in progressively older mice (Bray et al., 1998).
The guinea pig-adapted strain was isolated after 4 passages of
the human strain in guinea pigs (Connolly et al., 1999). After
challenge, the animals were weighted every day for 11 days and
monitored for clinical signs of infection for 30 days after the
challenge.
Passive transfer of pooled human immune globulin (Casimiro
et al.)
BALB/c and B10.BR mice were injected intravenously with
500 Al containing 120 mg of pooled human Ig (Panglobulin
NF; American Red Cross, Washington, DC) 24 and 2 h before
vaccination. At the time of vaccination, serum showed NAB
titer to AdHu5 at 1:1280. BALB/c mice were challenged as
indicated above.
Neutralizing antibody assay
Sera collected from immunized mice were inactivated at 56
-C for 45 min. Serial dilutions of each sample (1:10, 1:20, 1:40,
etc., in 50 Al of DMEM) was mixed with equal volume of Zaire
Ebola GP (ZGP)-pseudotyped HIV-based vector (see below for
details) encoding the LacZ reporter gene (15–30 transducing
units/well) and incubated at 37 -C for 60 min. The mixture was
then transferred onto subconfluent HeLa cells in 96-well flat-
bottomed plates and incubated for 90 min at 37 -C in 5% CO2.
Control wells were infected with equal amount of viral vector
without addition of serum or with non-immune serum. 100 Al of
DMEM supplemented with 20% FBS was then added to each
well and plates were incubated at 37 -C in 5%CO2 for 48 h Cellswere subsequently stained with X-gal and examined under a
microscope. Sample dilutions showed >50% reduction in the
number of blue cells compared to controls that scored positive
for neutralizing antibody. ZGP-pseudotyped HIV vector was
produced as previously described (Kobinger et al., 2001).
Briefly, 180 Ag of endotoxin-free DNA mixture, containing
ZEBOV/GP expression vector, HIV packaging plasmid, and
transfer vector encoding for LacZ in a 3:1:2 molar ratio, was
transfected into each 150 mm plate of 293T cells using CalPhos
Mammalian Transfection Kit (BD Biosciences Clontech). At 44
h after transfection, medium was added to each plate for 16
h before collection of vector. Cell-free supernatant containing
virus was further concentrated by ultracentrifugation at 28,000
rpm for 2 h at 4 -C using a SW28 rotor (Beckman, Fullerton,
CA). Concentrated virus was then resuspended into complete
DMEM and stored at 80 -C in small aliquots.
Frequency of INF-c positive CD8 T cells
Splenocytes (1  106/sample) were culture for 5 h at 37 -C
in 96-well round bottom microtiter plate wells in DMEM
supplemented with 10% FBS and 106 M 2-ME. GolgiStop
(BD PharMingen, San Diego, CA) was added at 1 Al/ml. The
TELRTFSI peptide was used for stimulation at a concentration
of 2 Ag/ml. Control cells were incubated with an unrelated
peptide or without peptide. After washing, cells were stained
with 100 Al of 1/100 dilution of a FITC-anti mouse CD8a (BD
PharMingen) at 4 -C for 30 min. Cells were washed again and
permeabilized in 1  Cytofix/Cytoperm (BD PharMingen) for
20 min at 4 -C, washed with 1 Perm/Wash (BD PharMingen),
and stained with 100Al of 1:100 dilution of a PE-anti mouse
IFN-g (BD PharMingen) in the same buffer at 4 -C for 30 min.
After washing, cells were examined by two-color flow
cytometry using an EPICS Elite XL (Beckman Coulter, Miami,
FL), and data were analyzed by WinMDi software. The
TELRTFSI (Rao et al., 1999) peptide which carries the
immunodominant MHC class I epitope of ZEBOV GP for
mice of the H-2k haplotype was synthesized by Mimotopes
(Clayton-Victoria, Australia). Peptide was diluted in DMSO to
a concentration of 5 mg/ml and stored at 80 -C.
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